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Hendrik-Tobias Arkenau o, Nayyer Iqbal p, Sramila Aithal q,
Margaret Block r, Soeren Cold s, Mathilde Cancel t, Olwen Hahn u,
Teja Poosarla v, Erica Stringer-Reasor w, Marco Colleoni x,
David Cameron y, Giuseppe Curigliano z, Muriel Siadak aa,
Kendra DeBusk ab, Jorge Ramos ac, Wentao Feng ad, Karen Gelmon aea Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
b Manchester Breast Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health,
University of Manchester, Manchester, UK
c Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
d Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
e Northside Hospital, Sandy Springs, GA, USA
f Kaiser Foundation Research Institute, Oakland, CA, USA
g Sygehus Lillebaelt - Vejle Sygehus, Denmark
h University Hospital of Besançon, Besançon, France
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TrastuzumabAbstract Aims: In HER2CLIMB, tucatinib significantly improved progression-free and
overall survival in patients with human epidermal growth factor receptor 2epositive (HER2þ)
metastatic breast cancer. We evaluated the impact of tucatinib on health-related quality of life
(HR-QoL) in HER2CLIMB.
Methods: Patients were randomised 2:1 to tucatinib or placebo combined with trastuzumab
and capecitabine. Starting with protocol version 7, the EuroQol 5 Dimensions 5 Levels
(EQ-5D-5L) questionnaire and EQ visual analogue scale (VAS) were administered at day 1
of cycle 1, every two cycles during cycles 3e9, every three cycles during cycle 12 and
thereafter and at each patient’s 30-day follow-up visit.
Results: Among 364 patients eligible for HR-QoL assessment, 331 (91%) completed 1 assess-
ment. EQ-VAS scores were similar for both arms at baseline and maintained throughout treat-
ment. EQ-5D-5L scores were similar between the treatment arms, stable throughout
therapy and worsened after discontinuing treatment. Risk of meaningful deterioration (7
points) on EQ-VAS was reduced 19% in the tucatinib vs. placebo arm (hazard ratio [HR]:
0.81; 95% confidence interval [CI]: 0.55, 1.18); the median (95% CI) time to deterioration
was not reached in the tucatinib arm and was 5.8 months (4.3, -) in the placebo arm. Among
patients with brain metastases (n Z 164), risk of meaningful deterioration on EQ-VAS was
reduced 49% in the tucatinib arm (HR: 0.51; 95% CI: 0.28, 0.93); the median (95% CI) time
to deterioration was not reached in the tucatinib arm and was 5.5 months (4.2, -) in the pla-
cebo arm.
Conclusions: HR-QoL was preserved for patients with HER2þ metastatic breast cancer who
were treated with tucatinib added to trastuzumab and capecitabine and maintained longer
with tucatinib therapy than without it among those with brain metastases.
Clinical Trial Registration: NCT02614794
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As our understanding of the molecular mechanisms of
human epidermal growth factor receptor 2epositive
(HER2þ) breast cancer improves and targeted treat-
ment strategies are developed, patients are living longer
with this disease [1]. HER2þ metastatic breast cancer
causes symptoms that impair health-related quality of
life (HR-QoL), and treatment can exacerbate symptoms
or lead to adverse events that further impact HR-QoL,
including physical, emotional, caregiver and financialburden [2]. As disease progresses and patients receive
later lines of systemic therapy, this burden increases and
survival and HR-QoL deteriorate further [3e6]. The
burden is even greater for those with brain metastases
because they have a worse prognosis and suffer from
neurological symptoms and treatment-related adverse
events, leading to further deterioration in HR-
QoL [7e11]. In this setting of long-term therapy,
reducing the impact of both illness and treatment on
physical and psychosocial well-being takes on renewed
importance [12]. Guideline-recommended treatments for
V. Mueller et al. / European Journal of Cancer 153 (2021) 223e233 225patients with HER2þ metastatic breast cancer are first-
line trastuzumab plus pertuzumab and a taxane, fol-
lowed by second-line trastuzumab emtansine (T-DM1)
for patients who have disease progression [13,14].
For patients whose disease progresses after two lines of
HER2-targeted therapy, there is no established consensus
on the standard of care, and the treatment landscape is
continually evolving. Besides trastuzumab and capecita-
bine, HER2-targeted tyrosine kinase inhibitors (TKIs)
are often prescribed in combination with other chemo-
therapies [13,14]. However, tolerability can be an issue
with the HER2-directed TKIs owing to off-target effects
on the epidermal growth factor receptor (EGFR) recep-
tor, resulting in high incidence of diarrhoea, including
severe diarrhoea and skin toxicity [15,16].
Tucatinib is an oral TKI that is highly selective for
the HER2 receptor, with minimal inhibition of other
HER2 receptors, including EGFR [17]. Tucatinib is
approved in combination with trastuzumab and cape-
citabine in the United States, the European Union and
several other countries for patients with HER2þ meta-
static breast cancer, including those with brain metas-
tases, whose cancers have progressed on at least one
(United States) or two (European Union) prior anti-
HER2 regimens in the metastatic setting. In the
pivotal HER2CLIMB trial, the combination of tucati-
nib, trastuzumab and capecitabine became the first
regimen to demonstrate a statistically significant and
clinically meaningful improvement in progression-free
survival and overall survival among patients with
HER2þ metastatic breast cancer who progressed on
trastuzumab, pertuzumab and T-DM1, both with and
without brain metastases [18]. The addition of tucatinib
to trastuzumab and capecitabine was well tolerated,
with adverse event rates similar to those observed with
trastuzumab and capecitabine alone [18].
We evaluated the impact of adding tucatinib to a
trastuzumab-capecitabine regimen on patient-reported
HR-QoL in patients in the HER2CLIMB trial.
2. Methods
2.1. Study design
HER2CLIMB is a randomised, double-blind trial of
tucatinib vs. placebo in combination with trastuzumab
and capecitabine in patients with HER2þ metastatic
breast cancer previously treated with trastuzumab,
pertuzumab and T-DM1 [18]. Patients were randomly
assigned 2:1 to receive either tucatinib (300 mg) or
placebo orally twice daily, in combination with trastu-
zumab (6 mg/kg intravenously once every 21 days, with
an initial loading dose of 8 mg/kg) and capecitabine
(1000 mg/m2 orally twice daily on days 1e14 of each
21-day cycle). In HER2CLIMB, 48% of participants
had the presence or history of brain metastases at
baseline, which included previously untreated, treatedstable, and treated and progressing brain metastases.
Patients were stratified at randomisation based on the
presence or history of brain metastases (yes or no),
Eastern Cooperative Oncology Group performance
status score (0 or 1) and region of world (US, Canada or
rest of the world). All patients underwent contrast
magnetic resonance imaging (MRI) of the brain at
baseline, and those with brain metastases on the baseline
scan underwent MRI of the brain every 6 weeks for 24
weeks and every 9 weeks thereafter.
The HER2CLIMB trial was conducted in accordance
with regulatory requirements and International
Conference on Harmonisation Good Clinical Practice
guidelines. The protocol was approved by institutional
review boards and ethics committees, as per the practice
at each participating trial site, and informed consent was
obtained for experimentation with human subjects.
2.2. HR-QoL assessments
Assessment of HR-QoL as an exploratory end-point
was initiated with protocol version 7 on 30th August
2017, and therefore, it was only administered to patients
enrolled after this date. Patients completed the HR-QoL
questionnaire before treatment administration at day 1
of cycle 1, every two cycles during cycles 3e9, every
three cycles starting at cycle 12 and beyond and at each
patient’s 30-day follow-up visit after stopping treatment
(regardless of the number of cycles completed). For
example, a patient who stopped treatment in cycle 5
would not have data reported at cycles 7 and 9 but
would have data reported for 30-day follow-up.
The HR-QoL assessment tool was the EuroQol 5
Dimensions 5 Levels (EQ-5D-5L) questionnaire, which
consists of five dimensions (mobility, usual activities,
self-care, pain/discomfort and anxiety/depression), each
rated on a 5-point scale (no problems, slight problems,
moderate problems, severe problems and extreme
problems) [19]. The EQ-5D-5L instrument also includes
a visual analogue scale (EQ-VAS) in which patients rate
their current overall health on a vertical visual analogue
scale that ranges from 0 (worst imaginable health state)
to 100 (best imaginable health state). Meaningful dete-
rioration in HR-QoL was defined as a decrease in the
EQ-VAS score from baseline of 7 points, based on a
minimally important difference of 7 points as estimated
by Pickard et al. [20]. EQ-5D-5L is validated for use in
patients, with breast cancer [21e23], approved by the
National Institute for Health and Care Excellence for
calculating quality-adjusted life years and also can be
used for economic evaluation of treatments in global
pivotal trials.
2.3. Statistical analysis
The HER2CLIMB trial was not powered for statistical
comparison of HR-QoL. We analysed EQ-5D-5L and
Fig. 1. CONSORT diagram of HER2CLIMB patients included in the HR-QoL analysis. TUC: tucatinib; Tras: trastuzumab; Cape:
capecitabine; PBO: placebo. )Two enrolled subjects did not undergo baseline brain MRI, one randomised to tucatinib and one rando-
mised to placebo. ))One patient in the TUC arm was missing information regarding brain metastases. MRI: magnetic resonance imaging;
HR-QoL: health-related quality of life.
Table 1
Demographic and disease characteristics of HER2CLIMB patients in the HR-QoL analysis.









Age, in years, median
(range)
55 (22, 79) 54 (25, 76) 54 (22, 75) 52 (25, 75)
Female, n (%) 217 (99.5) 111 (98) 107 (100) 56 (98)
ECOG performance status, n (%)
0 106 (49) 52 (46) 51 (48) 22 (39)
1 112 (51) 61 (54) 56 (52) 35 (61)
Stage at initial diagnosis, n (%)
Stage 0eIII 140 (64) 72 (64) 64 (60) 31 (54)
Stage IV 77 (35) 40 (35) 42 (39) 25 (44)
Not available 1 (0.5) 1 (1) 1 (1) 1 (2)
Histology, n (%)
ER and/or PR positive 135 (62) 71 (63) 64 (60) 34 (60)
ER and PR negative 79 (36) 42 (37) 41 (38) 23 (40)
Other 4 (2) 0 2 (2) 0
Prior lines of therapy, median (range)
Overall 4.0 (2, 11) 4.0 (2, 12) 4.0 (2, 11) 3.0 (2, 12)
Metastatic setting 3.0 (1, 11) 3.0 (1, 11) 2.0 (1, 11) 3.0 (1, 11)
Tucatinib combination: tucatinib, trastuzumab and capecitabine. Placebo combination: placebo, trastuzumab and capecitabine.
ECOG: Eastern Cooperative Oncology Group; ER: oestrogen receptor; PR: progesterone receptor; HR-QoL: health-related quality of life; MRI:
magnetic resonance imaging.
a Two enrolled subjects did not undergo baseline brain MRI, one randomised to tucatinib and one randomised to placebo.
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on the presence or absence of brain metastases. EQ-5D-
5L domain scores and EQ-VAS scores were summarised
by cycle for each treatment arm, with numerators rep-
resenting the number of patients who completed the
HR-QoL survey in that cycle and denominators repre-
senting the number of patients who completed the
baseline survey and were still on treatment in that cycle.
Time to meaningful deterioration on the EQ-VAS
(defined as a 7-point change from baseline [20]) was
estimated using the Kaplan-Meier method; patients who
did not have a 7-point change were censored at the
latest assessment before the data cut-off. The median
time to deterioration and 95% confidence interval (CI)
were computed for each treatment arm.
3. Results
HR-QoL data were available for 331 of 364 patients
(91%) who enrolled in the HER2CLIMB trial after HR-
QoL assessment was added to the protocol: 218 in theFig. 2.Median EQ-VAS scores at baseline, on treatment and at 30 days a
points) in the EQ-VAS score (B) in all patients with HR-QoL data. T
placebo; VAS: visual analogue scale. Thirty-day follow-up represent
treatment cycles completed. The centre line within the box represents t
reflect minimum and maximum. Numerators are the number of patient
are the number of patients who completed the baseline survey and wer
placebo arm did not have EQ-VAS data available. HR-QoL: health-rtucatinib arm and 113 in the placebo arm (Fig. 1).
Overall, this represents 54% (331 of 612) of all patients
who were enrolled in HER2CLIMB. This population
included 164 patients with brain metastases: 107 patients
in the tucatinib arm and 57 patients in the placebo arm.
Baseline demographic and disease characteristics were
similar between all HR-QoL patients and the HR-QoL
patients with brain metastases (Table 1) and consistent
with those of the overall HER2CLIMB population [18].
These patients had a median of 4 (range: 2 to 12) lines of
prior therapy overall and 3 (range: 1 to 11) lines of prior
therapy in the metastatic setting (Table 1).
3.1. Outcomes in all patients
EQ-VAS scores were similar between treatment arms at
baseline and were maintained throughout treatment in
both arms (Fig. 2A). There was a 19% reduction in the
risk of meaningful deterioration in HR-QoL in the
tucatinib arm compared with the placebo arm (hazard
ratio [HR]: 0.81; 95% CI: 0.55, 1.18); the medianfter stopping treatment (A) and time to meaningful deterioration (‡7
UC: tucatinib; trasTras: trastuzumab; Cape: capecitabine; PBO:
s 30 days after stopping treatment, regardless of the number of
he median. The box represents the interquartile range. Error bars
s who completed the HR-QoL survey in that cycle. Denominators
e still on treatment. One patient each in the tucatinib arm and the
elated quality of life; CI: confidence interval; HR: hazard ratio.
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the tucatinib arm and was 5.8 months (4.3, e) in the
placebo arm (Fig. 2B).
In all five EQ-5D-5L domains, most patients in both
treatment arms reported only slight or no problems, and
few patients reported moderate, severe or extreme
problems while on therapy (Fig. 3AeE). The proportion
of patients with slight or no problems was similar
between treatment arms and remained stable
throughout therapy. For each EQ-5D-5L domain, there
was an increase in the proportion of patients reporting
moderate, severe or extreme problems 30 days after
stopping treatment (Fig. 3AeE). Overall, these increases
were generally greater in the tucatinib arm than in the
placebo arm.
3.2. Outcomes in patients with brain metastases
As in the overall HR-QoL population, EQ-VAS scores
were similar for both treatment arms at baseline, wereFig. 3. EuroQol 5 Dimensions 5 levels (EQ-5D-5L) subscale responses at
patients with HR-QoL data: mobility (A), self-care (B), usual activities (C
represents 30 days after stopping treatment, regardless of the number
life.maintained throughout treatment and were not different
between treatment arms among patients with brain
metastases (Fig. 4B). There was a 49% reduction in the
risk of meaningful deterioration in HR-QoL in the
tucatinib arm compared with the placebo arm (HR:
0.51; 95% CI: 0.28, 0.93); the median (95% CI) time to
deterioration had not been reached in the tucatinib arm
and was 5.5 months (4.2, -) in the placebo arm (Fig. 4B).
For each EQ-5D-5L domain, there was an increase in
the proportion of patients reporting moderate, severe or
extreme problems 30 days after stopping treatment, with
the exception of anxiety/depression in the placebo arm
(Fig. 5AeE). Overall, these increases were generally
greater in the tucatinib arm than in the placebo arm.
Outcomes for HR-QoL patients with no brain me-
tastases are shown in Appendix A. EQ-VAS scores were
maintained throughout treatment and were not different
between treatment arms, and the risk of meaningful
deterioration in HR-QoL was similar between treatment
arms.baseline, on treatment and at 30 days after stopping treatment in all
), anxiety/depression (D) and pain/discomfort (E). 30-day follow-up
of treatment cycles completed. HR-QoL: health-related quality of
Fig. 4.Median EQ-VAS scores at baseline, on treatment, and at 30 days after stopping treatment (A) and time to meaningful deterioration (‡7
points) in the EQ-VAS score (B) in HR-QoL patients with brain metastases. TUC: tucatinib; trasTras: trastuzumab; Cape: capecitabine;
PBO: placebo; VAS: visual analogue scale. Thirty-day follow-up represents 30 days after stopping treatment, regardless of the number of
treatment cycles completed. The centre line within the box represents the median. The box represents the interquartile range. Error bars
reflect minimum and maximum. Numerators are the number of patients who completed the HR-QoL survey in that cycle. Denominators
are the number of patients who completed the baseline survey and were still on treatment. One patient each in the tucatinib arm and the
placebo arm did not have EQ-VAS data available. HR-QoL: health-related quality of life; CI: confidence interval; HR: hazard ratio.
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In the HER2CLIMB trial, patients with HER2þ meta-
static breast cancer, who had received at least two prior
anti-HER2edirected regimens, reported preservation of
overall HR-QoL when tucatinib was added to a trastu-
zumab and capecitabine regimen. Importantly, this
durability of HR-QoL throughout the treatment course
was reported in the context of a pivotal trial that
demonstrated better progression-free survival and overall
survival with the tucatinib regimen [18]. Furthermore,
EQ-5D-5L domain scores worsened after patients stopped
treatment to a greater degree among the tucatinib-treated
patients. Taken together, these findings demonstrate that
the tucatinib-trastuzumab-capecitabine regimen not only
provides significant and clinically meaningful anticancer
activity but also maintains HR-QoL.
Based on these findings, this triplet regimen has
minimal impact on HR-QoL, which indicates that side-
effects are not perceived as severe. Although diarrhoea,
sometimes severe, is common with HER2-directed
TKIs, [15,16], diarrhoea in HER2CLIMB patients
was manageable with short courses of antidiarrheal
medications (i.e., a median of three days per cycle) inboth the tucatinib and placebo arms [18]. Furthermore,
preservation of HR-QoL with the tucatinib regimen was
achieved without protocol-mandated use of prophylac-
tic antidiarrheal medication.
Up to 50% of patients with HER2þ metastatic breast
cancer will develop brain metastases, [24e27], and these
patients have an increased likelihood of reduced HR-
QoL compared with patients without brain metasta-
ses [8]. Patients with HER2þ breast cancer and brain
metastases also continue to have a poor prognosis and
impaired QoL, despite advances in HER2-targeted
treatments [8]. Historically, patients with brain metas-
tases, especially those with active (i.e., untreated or
progressing) brain metastases, have not been included in
clinical trials of treatments for HER2þmetastatic breast
cancer. In recent years, the American Society of Clinical
OncologyeFriends of Cancer Research Brain Metasta-
ses Working Group and the 2019 US Food and Drug
Administration ‘Cancer Clinical Trial Eligibility
Criteria: Brain MetastasesdGuidance for Industry’
have advocated for inclusion of patients with both
treated stable and active brain metastases in clinical
trials to increase applicability to this population with
high unmet need [28,29]. In this HR-QoL analysis from
Fig. 5. EuroQol- 5 Dimensions 5 levels (EQ-5D-5L) subscale responses at baseline, on treatment and at 30 days after stopping treatment in
HR-QoL patients with brain metastases: mobility (A), self-care (B), usual activities (C), anxiety/depression (D) and pain/discomfort
(E). Thirty-day follow-up represents 30 days after stopping treatment, regardless of the number of treatment cycles completed.
V. Mueller et al. / European Journal of Cancer 153 (2021) 223e233230HER2CLIMB, nearly half of the patients had brain
metastases, which was consistent with the overall
HER2CLIMB population. To our knowledge, the
combination of delayed progression, improved
survival and prolonged HR-QoL seen in tucatinib-
treated patients with brain metastases has not been
shown with other HER2-directed therapies. With brain
metastases in nearly half of the study population, these
findings are likely to better reflect real-world outcomes
than trials that excluded patients with brain metastases.
Although HER2CLIMB was a large, global, multi-
centre study with good representation of patients with
brain metastases, it was not powered for statistical
comparison of HR-QoL end-points. Nonetheless, there
was a trend towards better preservation of overall HR-
QoL in the tucatinib arm than in the placebo arm.
Although HR-QoL assessment was not part of the
initial protocol, once implemented, 91% of enrolled
patients completed at least one assessment and were
eligible for analysis. And although <50% of subjectscompleted the EQ-5D-5L at the 30-day follow-up visit
(regardless of the number of treatment cycles), attrition
was similar in both treatment arms. The lower patient
numbers in cycles 7 and 9 reflect both missed assess-
ments and fewer patients still on treatment during later
cycles. We cannot rule out the possibility of attrition
bias, whereby patients who felt well were perhaps more
inclined to continue answering questionnaires
throughout the study than those who did not feel well.
5. Conclusions
HR-QoL is increasingly recognised as a valuable end-
point of cancer care by patients and their families, as
well as prescribers, regulators and payers. In patients
with HER2þ metastatic breast cancer, HR-QoL was
preserved throughout treatment with tucatinib in com-
bination with trastuzumab and capecitabine. In addi-
tion, among patients with brain metastases, HR-QoL
was maintained longer with tucatinib than without it.
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